| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03126864 Details | 2019-11-04 Interventional | 1 | 11 | Cyclophosphamid… Fludarabine Fludarabine pho… Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… Hematopoietic/L… | Terminated per the PI's request. - | |||
| NCT02553499 Details | 2019-11-04 Interventional | 1 | 37 | Pembrolizumab Neoplasms Advanced Solid … | Enrollment prematurely discontinued due to program prioritization & not due to any safety
concerns. Enrollment into this study was prematurely discontinued due to program prioritization and not related to any safety concerns. | |||
| NCT01264887 2009-013291-46 Details | 2019-11-04 Interventional | 3 | 31 | Tapentadol Cancer Pain Chronic Pain Neoplasms Cancer Pain | Administrative reasons The trial was stopped for administrative reasons. Three years after trial initiation 2 participants were in the trial and to permit analysis and reporting the sponsor decided to terminate the trial. | |||
| NCT01135537 Details | 2019-11-04 Interventional | 2 | 30 | Antilymphocyte … Thymoglobulin Genetic Disease… Metabolic Disea… Genetic Disorde… Malignancy Metabolic Disea… | The study was closed before 2017 due to inconclusive results from Lab - | |||
| NCT00859456 Details | 2019-11-04 Interventional | 2 | 10 | Sunitinib Sarcoma Sarcoma, Soft T… | Closed by pharmaceutical sponsor - | |||
| NCT00547118 Details | 2019-11-04 Interventional | 2 | 17 | Rimonabant Psychotic Disor… Schizophrenia Hypertension Obesity Schizoaffective… Smoking | Withdrawn due to medication withdrawal from the EMEA - | |||
| NCT03374709 Details | 2019-11-01 Interventional | 4 | 0 | Oxcarbazepine Neuralgia Trigeminal Neur… | Resource and time constraints were encountered by product manufacturer and study team. - | |||
| NCT03280342 Details | 2019-11-01 Interventional | 2 | 0 | Topiramate Headache Migraine Disord… Migraine | Sponsor terminated study - | |||
| NCT02267707 Details | 2019-11-01 Interventional | 1 | 1 | Gemcitabine Paclitaxel Cholestasis Hyperbilirubine… Pancreatic Neop… | Study population more infrequent than estimated. No study-related safety issues and no safety
concerns were identified for the study. - | |||
| NCT03345940 2017-000559-26 Details | 2019-10-31 Interventional | 4 | 55 | Dimethyl Fumara… Fingolimod Hydr… Multiple Sclero… Multiple Sclero… Sclerosis Relapsing Remit… | termination of the study due to the slowness of the recruitment activity, according to the
contract signed with the Sponsor - | |||
| NCT00850993 2009-017434-45 Details | 2019-10-30 Interventional | 2 | 58 | Tin mesoporphyr… Hyperbilirubine… Hyperbilirubine… | To redefine study population It should be noted that the study was discontinued before enrollment of the full 4.5 mg/kg cohort,and therefore, the stannsoporfin 4.5 mg/kg treatment group included 8 patients and the placebo group included 15 patients. | |||
| NCT03697824 Details | 2019-10-29 Interventional | 2 | 0 | Cyclophosphamid… Fludarabine Pembrolizumab Sarcoma Sarcoma, Synovi… Neoplasms | Internal decision, study will be replaced with a larger monotherapy trial - | |||
| NCT03610100 Details | 2019-10-29 Interventional | 2/3 | - | Gemcitabine Carcinoma Carcinoma, Acin… Pancreatic Neop… Pancreatic Acin… | Suspended to recruitment following TSC review on efficacy and toxicities - | |||
| NCT03504033 Details | 2019-10-29 Interventional | 4 | 0 | Desflurane Liver Function … | A device would have had to be maintained. The maintenance company is insolvent; both another
maintenance company and another serviced device were not available. - | |||
| NCT02448251 Details | 2019-10-29 Interventional | 1 | 28 | Abivertinib Carcinoma, Non-… Lung Neoplasms Non Small Cell … | - - | |||
| NCT01832350 Details | 2019-10-29 Interventional | 4 | 34 | Dextromethorpha… Quinidine Alzheimer Disea… Alzheimer's Dis… Pseudobulbar Af… | Sponsor decided to stop study early - | |||
| NCT03965624 2018-004556-38 Details | 2019-10-28 Interventional | 2 | 0 | Ixazomib Anemia, Hemolyt… Anemia, Hemolyt… Cytopenia Purpura, Thromb… Thrombocytopeni… Immune Thromboc… Warm Autoimmune… | Decision of sponsor: impossibility of contract with Takeda - | |||
| NCT02007447 Details | 2019-10-28 Interventional | 2/3 | 30 | Oxytocin Autism Spectrum… Autistic Disord… Child Developme… | Most of our patients had no willingness to participate in the survey - | |||
| NCT01485094 2011-002092-42 Details | 2019-10-28 Interventional | 2 | 114 | Pregabalin Neuralgia | The trial was early terminated after it was concluded that there was no added benefit from
exposing further participants after an unblinded interim analysis. - | |||
| NCT01024686 Details | 2019-10-28 Interventional | 1/2 | [1 Refs] | 6 | Vaccines Malaria | - - |